184 completed, 37 recruiting, 35 terminated, 33 unknown. 341 Phase 2, 92 Phase 1, 43 Phase 3.
Follow Motor Neuron Disease: new trials by email Literature Review of Motor Neuron Disease trials Research Report on Motor Neuron Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS) Q-Cells - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Not yet recruiting | Q Therapeutics, Inc. | 30 | 2026-12-01 | 2026-07-08 |
| Personalized Antisense Oligonucleotide Therapy for a Participant With TARDBP ALS nL-TARDB-002 - Amyotrophic Lateral Sclerosis (ALS) | Phase 1 / Phase 2 | Enrolling by invitation | n-Lorem Foundation | 1 | 2026-12-01 | 2026-07-14 |
| A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS) BIIB147, Placebo - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Recruiting | Biogen | 69 | 2026-10-07 | 2026-10-26 |
| Colchicine Effect on Amyotrophic Lateral Sclerosis Patients Colchicine 0.5 MG Oral Tablet, Placebo Oral Tablet - Amyotrophic Lateral Sclerosis | Phase 2 | Not yet recruiting | Azienda Ospedaliero-Universitaria di Modena | 87 | 2026-10-01 | 2026-09-10 |
| Efficacy and Safety of Cyclophosphamide in Amyotrophic Lateral Sclerosis Cyclophosphamide, Riluzole - Amyotrophic Lateral Sclerosis | Phase 2 | Not yet recruiting | Huashan Hospital | 60 | 2026-10-01 | 2026-09-22 |
| Efficacy and Safety of Tazbentetol in ALS Participants Tazbentetol, placebo - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Not yet recruiting | Spinogenix | 430 | 2026-10-01 | 2026-09-10 |
| Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis RNS60, Placebo - Amyotrophic Lateral Sclerosis | Phase 2 | Withdrawn | Revalesio Corporation | 2026-10-01 | 2026-04-16 | |
| The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab Foralumab Nasal, Placebo - ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis | Phase 2 | Enrolling by invitation | Tiziana Life Sciences LTD | 44 | 2026-09-23 | 2026-10-28 |
| A Phase II Study of ALT001 in Patients With Amyotrophic Lateral Sclerosis (ALS) ALT001 1.0 μg/kg, ALT001 2.0 μg/kg, Placebo - Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | Not yet recruiting | Darwin Origin (Hubei) Biopharmaceutical Co., Ltd. | 150 | 2026-09-01 | 2026-09-22 |
| FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS TRCN-1023, Placebo - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Recruiting | Trace Neuroscience, Inc. | 30 | 2026-08-20 | 2026-10-14 |
| Therapeutic Approach of Repeated Transient Blood-brain Barrier Opening in Amyotrophic Lateral Sclerosis. SonoCloud-4 (SC4) device - Amyotrophic Lateral Sclerosis, Charcot Disease | Phase 1 / Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 23 | 2026-07-15 | 2026-08-10 |
| A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I SKG0201 Injection - Spinal Muscular Atrophy 1 | Phase 1 / Phase 2 | Recruiting | Lanyue Biotech (Hangzhou) Co., Ltd. | 11 | 2026-07-15 | 2026-10-14 |
| This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling Galunisertib + Nerandomilast Combination - ALS (Amyotrophic Lateral Sclerosis) | Phase 2 / Phase 3 | Not yet recruiting | Gipfel Life Sciences GmbH | 60 | 2026-06-30 | 2026-01-07 |
| A Clinical Trial of Early Ventilation in Amyotrophic Lateral Sclerosis (EVENT ALS) Non-invasive ventilation - Amyotrophic Lateral Sclerosis (ALS), Chronic Respiratory Failure | Phase 2 | Recruiting | University of Pennsylvania | 48 | 2026-06-11 | 2026-06-26 |
| TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis TP04HN106, Saline - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Recruiting | Talengen Institute of Life Sciences, Shenzhen, P.R. China. | 60 | 2026-06-04 | 2026-10-02 |
| A Study of LTX-002 in Adult Participants With Amyotrophic Lateral Sclerosis LTX-002, Placebo (aCSF) - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Recruiting | Leal Therapeutics, Inc | 56 | 2026-04-29 | 2026-08-18 |
| A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS Patients PLL001 or placebo daily subcutaneous injections - Amyotrophic Lateral Sclerosis, ALS | Phase 1 / Phase 2 | Not yet recruiting | PLL TX AUSTRALIA PTY LTD | 153 | 2026-04-08 | 2026-03-19 |
| Research of Traditional Chinese Medicine Oral Preparation of C. Cicadae in the Treatment of ALS Patients With Elevated Plasma Sphingolipids C. cicadae, Control - Amyotrophic Lateral Sclerosis | Phase 2 | Not yet recruiting | The Third Xiangya Hospital of Central South University | 84 | 2026-04-01 | 2026-05-20 |
| A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis. NB-4746 High dose, NB-4746 Low dose, Placebo - Amyotrophic Lateral Sclerosis (ALS) | Phase 1 / Phase 2 | Recruiting | Nura Bio | 80 | 2026-03-04 | 2026-09-17 |
| Personalized Antisense Oligonucleotide Therapy for A Single Patient With CHCHD10 ALS (nL18576) nL-CHCHD-001 - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Not yet recruiting | n-Lorem Foundation | 1 | 2026-03-01 | 2026-02-20 |
Showing 20 of 341. Sign in to see all of them.
Amyotrophic Lateral Sclerosis (274) · Muscular Atrophy, Spinal (40) · Bulbo-Spinal Atrophy, X-Linked (23) · Spinal Muscular Atrophies of Childhood (16) · Neuromuscular Diseases (10) · Neurodegenerative Diseases (8) · Prostatic Neoplasms (7) · Nervous System Diseases (6) · Nerve Degeneration (5) · Central Nervous System Diseases (4) · Multiple Sclerosis (4) · Parkinson Disease (4) · Breast Neoplasms (3) · Depression (3)
Spinal Cord Diseases (339) · Central Nervous System Diseases (337) · Nervous System Diseases (335) · Neurodegenerative Diseases (333) · Neuromuscular Diseases (331) · Metabolic Diseases (274) · Nutritional and Metabolic Diseases (274) · Proteostasis Deficiencies (274) · TDP-43 Proteinopathies (273) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (42) · Genetic Diseases, Inborn (41) · Heredodegenerative Disorders, Nervous System (41) · Muscular Atrophy, Spinal (31) · Pathological Conditions, Signs and Symptoms (31)
Riluzole (15) · Risdiplam (7) · 4-phenylbutyric acid (6) · Sodium Chloride (6) · Memantine (5) · bicalutamide (5) · nusinersen (5) · CK-2017357 (4) · Creatine (4) · Sugars (4) · Tamoxifen (4) · sodium phenylbutyrate and taurursodiol (4) · Carnitine (3) · Celecoxib (3) · Copper (3)
Hoffmann-La Roche (9) · Merit E. Cudkowicz, MD (9) · Novartis Pharmaceuticals (7) · n-Lorem Foundation (7) · Biogen (6) · Cytokinetics (6) · Massachusetts General Hospital (6) · Amylyx Pharmaceuticals Inc. (4) · Duke University (4) · Peking University Third Hospital (4) · Phoenix Neurological Associates, LTD (4) · University of Utah (4) · Assistance Publique - Hôpitaux de Paris (3) · Azienda Ospedaliero-Universitaria di Modena (3) · Brainstorm-Cell Therapeutics (3)
United States (177) · Italy (45) · Germany (43) · Canada (40) · France (35) · Netherlands (35) · Belgium (33) · United Kingdom (30) · Australia (28) · China (26) · Spain (26) · Poland (20) · Japan (16) · Sweden (13) · South Korea (11)
Merit Cudkowicz, MD (10) · Jeremy Shefner, MD, PhD (6) · Dominic Rowe, MD (3) · Dongsheng Fan (3) · Merit Cudkowicz, MD, MSc (3) · Thomas Meyer, MD (3) · Todd D Levine, MD (3) · Dr Ching H. Wang (2) · Jinsy Andrews, MD (2) · Johnny Salameh, MD (2) · Jonathan Katz, MD (2) · Kathryn J Swoboda, M.D. (2)
PMID 36008843, PMID 37148485, PMID 41224659, PMID 26751635, PMID 27939059, PMID 31420846, PMID 35577511, PMID 37396808, PMID 39457678, PMID 40067754, PMID 40067755, PMID 40067821, PMID 11750036, PMID 17182796, PMID 18270879, PMID 18425621, PMID 19192301, PMID 19268425, PMID 19682544, PMID 19727208, PMID 19743457, PMID 19846582, PMID 20363190, PMID 20808854, PMID 21216197, PMID 21423758, PMID 21607987, PMID 21625426, PMID 21754985, PMID 22101764, PMID 22415951, PMID 22591195, PMID 22714021, PMID 22715372, PMID 23039386, PMID 23217177, PMID 23952636, PMID 24300782, PMID 24582471, PMID 24820540, PMID 24876969, PMID 25324884, PMID 25664595, PMID 25787192, PMID 25934946, PMID 25982504, PMID 26444282, PMID 27589059, PMID 27938483, PMID 28139349
2023 (9), 2017 (6), 2025 (5), 2014 (3), 2016 (3), 2015 (2), N01NS42361 (2), 2005 (1), 2018 (1), 2019 (1), M01RR000036 (1), M01RR000109 (1), R01HD054599 (1), R01NS048125 (1), R21HD054697 (1)